Florida Cancer Specialists & Research Institute Innovations in Precision Oncology Informatics Showcased at World Conference

Press Release

In Partnership With

Florida Cancer Specialists

Trevor Heritage, PhD presents insights at PMWC® 2024

Fort Myers, Fla., January 23, 2024 – Florida Cancer Specialists & Research Institute, LLC (FCS) Senior Vice President & Data Officer Trevor Heritage, PhD will share learnings gained from the statewide practice’s development of an innovative propriety precision oncology platform at the Precision Medicine World Conference (PMWC® 2024) being held this month in Santa Clara, California. Dr. Heritage joins top global researchers and medical professionals across healthcare and biotechnology sectors at the three-day event, recognized as the foremost precision medicine conference.

“FCS PRECISE™, our propriety precision oncology system, is critical in precision oncology decision-making, leading to optimal experiences and outcomes for our patients,” said Dr. Heritage. “I am delighted to join with other industry pioneers to help accelerate advances that will enable effective adoption of precision medicine in community oncology.”

The FCS PRECISE™ system aggregates and standardizes discrete, genomic variant information derived from next-generation sequencing (NGS) testing conducted at FCS’ in-house molecular laboratory, as well as external references labs. Dr. Heritage heads FCS’ growing Precision Oncology Informatics Team focused on optimizing the delivery and integration of molecular data and decision-support capabilities to physicians and patients.

“Thanks to our forward-thinking investments, we are now able to leverage our in-house data to accurately examine each patient’s unique molecular biomarkers and identify very specific and targeted treatments, including matches for clinical trial opportunities, and we are able to do it much faster and more completely than ever before,” added Lucio N. Gordan, MD, FCS President & Managing Physician, who has spearheaded precision medicine initiatives throughout his tenure. More than 57,500 patient cases have been analyzed and 64,000 clinical trial matches identified to date, with volumes scaling rapidly.

Related Videos
Related Content